Britt Irene Chang 4

What Happened
Director Britt Irene Chang received equity awards from IDEXX Laboratories on 2026-05-12: 525 option units and 234 deferred stock units (total 759 units). The filing reports an acquisition of these derivative awards at $0.00 (no cash paid at grant); the filing does not show a cash value or an exercise price for the options in the provided excerpt. These are awards/grants (not open-market purchases or sales) and are typical director compensation rather than a sale or immediate purchase.

Key Details

• Transaction date: 2026-05-12; Form 4 filed 2026-05-14 (timely filing).
• Reported grants: 525 option units (derivative), 234 deferred stock units (derivative); both shown at $0.00 in the filing.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnotes:
  • F1 — The 525 option units are options to buy common stock that vest in one installment on the one-year anniversary of the grant or on the date of the 2027 annual meeting, whichever is earlier.
  • F2 — Each deferred stock unit (234) is a contingent right to one share; they vest in one installment on the one-year anniversary or at the 2027 annual meeting and by default are payable as common stock following a director’s resignation.
• No indication of a 10b5-1 plan, cashless exercise, tax withholding sale, or gift in the excerpt.

Context
These awards are standard non-cash director compensation meant to align board members with shareholder interests. Options create a future right to buy shares (subject to vesting and exercise terms); deferred stock units convert to shares at vesting or upon specified events. Because this is a grant (not a sale), it does not directly signal buying or selling sentiment by the director.